[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@Naveris_inc](/creator/twitter/Naveris_inc) "Naveris executive chairman founder and chief science & technology officer Piyush Gupta PhD joins a roundtable discussion on Evolving Technologies for Molecular Residual Disease Testing in Solid Tumors Perspectives on Platforms and Clinical Utility sponsored by @QIAGEN. On October XX at 12:00pm Eastern Dr. Gupta and other clinical oncology and biotech experts will discuss evolving best practices for MRD testing in solid tumors reflect on clinical questions that future studies will need to answer and explore how different technologies like dPCR and next-gen sequencing may be better 'fit for" [X Link](https://x.com/Naveris_inc/status/1979272144556114091) [@Naveris_inc](/creator/x/Naveris_inc) 2025-10-17T19:43Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Naveris_inc
"Naveris executive chairman founder and chief science & technology officer Piyush Gupta PhD joins a roundtable discussion on Evolving Technologies for Molecular Residual Disease Testing in Solid Tumors Perspectives on Platforms and Clinical Utility sponsored by @QIAGEN. On October XX at 12:00pm Eastern Dr. Gupta and other clinical oncology and biotech experts will discuss evolving best practices for MRD testing in solid tumors reflect on clinical questions that future studies will need to answer and explore how different technologies like dPCR and next-gen sequencing may be better 'fit for"
X Link @Naveris_inc 2025-10-17T19:43Z XXX followers, XX engagements
/creator/twitter::1849230415/posts